Anchor Ventures: FDA Modernization: Opportunities for Patient Impact and Economic Development

Each new drug requires over 15 years and $2B before it is approved for use in patients. New tools — including AI models for drug discovery, bioprinting of organoids, and organs-on-a-chip — promise to reduce the cost and timeline, but have not yet been integrated into the regulatory pathways. The FDA Modernization Act of 2022 opened the door to the use of cutting-edge platforms in clinical and nonclinical development, providing a generational opportunity. Join panelists as they discuss the patient impact and the economic development opportunities presented by FDA Modernization.